rs7025486 — DAB2IP DAB2IP intron variant

DAB2IP — The Vascular Gatekeeper That Guards Against Aortic Aneurysm

Your aorta — the body's largest artery — depends on a delicate balance between cellular growth, inflammation, and structural integrity. DAB2IP (DAB2 Interacting Protein) is a Ras GTPase-activating protein¹¹ Ras GTPase-activating protein
a molecular brake that limits uncontrolled cell proliferation by inactivating Ras signaling and simultaneously restrains NF-κB-driven inflammation. When DAB2IP function is reduced, vascular smooth muscle cells proliferate unchecked, inflammatory signaling escalates, and the structural integrity of vessel walls deteriorates. The rs7025486 A allele reduces DAB2IP expression — a change that leaves the vascular wall more susceptible to the widening, weakening, and eventual rupture that defines an abdominal aortic aneurysm (AAA).

The Mechanism

rs7025486 is located in an intron of the DAB2IP gene on chromosome 9q33.2. As an intronic variant, it does not change the amino acid sequence of the protein; instead, it influences gene expression — how much DAB2IP the cell produces²² gene expression — how much DAB2IP the cell produces
likely through effects on transcription factor binding, chromatin accessibility, or enhancer activity in vascular tissues. The A allele has been shown in functional studies to associate with reduced DAB2IP transcript and protein levels in vascular smooth muscle cells.

DAB2IP acts through two parallel anti-inflammatory mechanisms. First, it promotes RasGAP activity³³ RasGAP activity
DAB2IP accelerates the hydrolysis of Ras-GTP to Ras-GDP, thereby switching off Ras-MAPK pro-growth signaling in vascular smooth muscle cells. Second, it suppresses the NF-κB pathway⁴⁴ NF-κB pathway
the master regulator of inflammatory gene expression, including cytokines, matrix metalloproteinases, and adhesion molecules that degrade the extracellular matrix of the aortic wall. When the A allele reduces DAB2IP levels, both brakes loosen simultaneously: smooth muscle cells proliferate more aggressively, and inflammatory mediators accumulate — creating conditions that progressively weaken the aortic wall. Matrix metalloproteinases released under NF-κB drive enzymatically digest the collagen and elastin scaffold that gives the aorta its tensile strength, initiating the progressive dilation characteristic of AAA.

The Evidence

The AAA association was first established definitively in 2010. Gretarsdottir et al. in Nature Genetics⁵⁵ Gretarsdottir et al. in Nature Genetics
Sequence variant within DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet 2010;42:692–697 genotyped 1,292 AAA cases and 30,503 controls in discovery, with replication in up to 3,267 cases and 7,451 controls. The A allele showed an odds ratio of 1.21 (p = 4.6×10⁻¹⁰) for AAA⁶⁶ odds ratio of 1.21 (p = 4.6×10⁻¹⁰) for AAA
genome-wide significance by a comfortable margin, with consistent replication across all cohorts. Critically, the same allele was also associated with early-onset myocardial infarction (OR 1.18, p = 3.1×10⁻⁵), peripheral arterial disease (OR 1.14, p = 3.9×10⁻⁵), and pulmonary embolism (OR 1.20, p = 3×10⁻⁴)⁷⁷ early-onset myocardial infarction (OR 1.18, p = 3.1×10⁻⁵), peripheral arterial disease (OR 1.14, p = 3.9×10⁻⁵), and pulmonary embolism (OR 1.20, p = 3×10⁻⁴)
indicating a broader role across the vascular disease spectrum rather than AAA-specific pathology.

A large multi-cohort GWAS for myocardial infarction⁸⁸ large multi-cohort GWAS for myocardial infarction
Hartiala et al. European Heart Journal 2021, approximately 831,000 total subjects identified rs7025486 as a genome-wide significant susceptibility locus for MI (OR ≈ 1.05, p = 4×10⁻⁸), confirming the cardiovascular-wide relevance of this variant in populations extending well beyond the original Icelandic cohort. The modest per-allele effect size is typical for common polygenic risk variants — but with an A allele frequency of ~26–32% across populations, the population-attributable risk is substantial.

The most recent confirmation comes from the largest AAA genomic study ever conducted. Roychowdhury et al. 2023 in Nature Genetics⁹⁹ Roychowdhury et al. 2023 in Nature Genetics
GWAS meta-analysis of 39,221 AAA cases and 1,086,107 controls across 14 cohorts confirmed rs7025486 as among the leading AAA loci (beta = 0.10 per A allele, p = 1×10⁻³⁰), and identified PCSK9 as a therapeutically tractable target downstream of lipid-mediated AAA pathogenesis — providing context that the DAB2IP pathway acts in concert with lipid and inflammatory mechanisms.

Practical Actions

No approved medication specifically targets the DAB2IP/Ras-GTPase pathway, but the AAA risk associated with rs7025486 is very much actionable through surveillance and well-established vascular risk modification. The critical intervention is ultrasound screening: AAA is asymptomatic until rupture, when mortality exceeds 80%. One-time screening of the abdominal aorta at age 65 detects aneurysms when repair is still elective and low-risk — with genetic risk factors such as this variant, earlier initiation (age 55–60 for A-allele carriers) is reasonable to discuss with a physician. A aortic diameter ≥ 5.5 cm in men or ≥ 5.0 cm in women triggers elective repair; diameters of 3.0–5.5 cm require periodic surveillance.

Smoking is the single strongest modifiable risk factor for AAA and more than doubles risk; for rs7025486 A-allele carriers, the genetic and environmental risks are multiplicative. Blood pressure control is also directly relevant: sustained hypertension increases aortic wall stress and accelerates aneurysm expansion. Each 10 mmHg reduction in systolic pressure is associated with an approximately 7% reduction in AAA rupture risk. Statins have observational and mechanistic support for slowing AAA progression, though no large RCT has demonstrated definitive surgical endpoint benefit.

Interactions

DAB2IP sits at the convergence of the Ras-MAPK and NF-κB pathways — both of which are also influenced by lipid-related genes. The rs7025486 risk is partially mediated through inflammatory amplification of atherogenic lipid stress, and individuals who also carry risk variants in lipid genes (e.g. rs562338 in APOB¹⁰¹⁰ rs562338 in APOB
elevated LDL drives additional vascular wall inflammation that compounds the reduced DAB2IP brake) may face compounded risk. The NF-κB pathway implicated by DAB2IP loss also overlaps with TNF and cytokine signaling; co-occurring variants in TNF-region genes warrant attention in individuals with this genotype.